论文部分内容阅读
CA15-3作为一种乳腺癌相关抗原,近年来被国内外所重视。我院自1995年以来用放射免疫法检测了血清CA15-3水平在乳腺癌术前诊断和术后复发监测方面的价值,现将结果报告如下。 对象和方法 对180例乳腺疾病患者进行血清CA15-3检测,其中乳腺良性疾病42例,乳腺癌138例,后者包括术前51例(临床国Ⅰ期17例,Ⅱ期28例,Ⅲ期6例),术后随访87例(其中复发或转移病人14例)。全部病例均经病理证实。 抽取受检者静脉血,分离血清,置-20℃保存。使用美国DPC-CA15-3试剂盒,设定阳性界值为30U/ml,用放射免疫法检测血清CA15-3水平。
As a breast cancer-associated antigen, CA15-3 has been taken seriously at home and abroad in recent years. Our hospital has been using radioimmunoassay to measure the serum CA15-3 levels since 1995 in the preoperative diagnosis and postoperative recurrence monitoring of breast cancer. The results are reported below. Subjects and Methods Serum CA15-3 was detected in 180 patients with breast disease, including 42 cases of benign breast disease and 138 cases of breast cancer. The latter included 51 cases before surgery (17 cases in clinical phase I, 28 cases in phase II, phase III). In 6 patients), 87 patients were followed up after surgery (including 14 patients with recurrent or metastatic disease). All cases were confirmed by pathology. The venous blood of the subject was taken and the serum was separated and stored at -20°C. Using the US DPC-CA15-3 kit, the positive limit was set to 30 U/ml and serum CA15-3 levels were determined by radioimmunoassay.